Casdin Capital’s Epizyme, Inc EPZM Stock Holding History

Casdin Capital’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-520,000	Closed	-$7.85M	–	35
2017 Q2	$7.85M	Buy	520,000 +35,000	+7%	+$529K	2.9%	14
2017 Q1	$8.32M	Buy	485,000 +210,000	+76%	+$2.8M	4.91%	7
2016 Q4	$3.33M	Sell	275,000 -20,000	-7%	-$209K	2.75%	14
2016 Q3	$2.9M	Sell	295,000 -45,000	-13%	-$411K	2.35%	14
2016 Q2	$3.48M	Sell	340,000 -205,000	-38%	-$2.29M	3.47%	14
2016 Q1	$6.61M	Buy	545,000 +212,500	+64%	+$2.15M	7.58%	2
2015 Q4	$5.33M	Buy	+332,500	New	+$4.93M	4.71%	12

Other funds holding EPZM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Casdin Capital's EPZM Position: Q3 2017 in Review

Casdin Capital sold out of Epizyme, Inc (EPZM) in Q3 2017, closing a stake of 520,000 shares — an estimated $7.85M sold.

Casdin Capital first reported a position in EPZM in Q4 2015 and held it in 7 quarters. The position peaked at $8.32M in Q1 2017. 104 funds tracked by Wall St. Rank hold EPZM as of Q3 2017.

Casdin Capital reported no remaining Epizyme, Inc position as of Q3 2017 after selling out during the quarter.
Casdin Capital sold 520,000 Epizyme, Inc shares in Q3 2017, an estimated $7.85M.
Casdin Capital first reported a position in Epizyme, Inc in Q4 2015 and held it in 7 quarters.
Casdin Capital's Epizyme, Inc position peaked at $8.32M in Q1 2017.
104 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2017.

Based on Casdin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.